Structure Therapeutics (GPCR) Current Assets (2022 - 2026)

Structure Therapeutics' Current Assets history runs 5 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• On a quarterly basis, Current Assets rose 75.44% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 75.44% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 76.2% from the prior year.
• Current Assets fell to $1.5 billion in Q1 2026 per GPCR's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Current Assets topped out at $1.6 billion in Q4 2025 and bottomed at $93.1 million in Q4 2022.
• The 5-year median for Current Assets is $806.7 million (2025), against an average of $712.6 million.
• Across the five-year window, Current Assets soared 408.77% in 2023 and retreated 14.75% in 2025, its largest moves.
• Year by year, Current Assets stood at $93.1 million in 2022, then surged by 408.77% to $473.6 million in 2023, then surged by 88.17% to $891.2 million in 2024, then surged by 76.2% to $1.6 billion in 2025, then dropped by 5.08% to $1.5 billion in 2026.
• Per Business Quant, the three latest GPCR Current Assets figures stand at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $814.0 million (Q3 2025).